171 related articles for article (PubMed ID: 32291777)
1. Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
Nguyen MN; Nayernama A; Jones SC; Kanapuru B; Gormley N; Waldron PE
Am J Hematol; 2020 Sep; 95(9):E218-E222. PubMed ID: 32291777
[No Abstract] [Full Text] [Related]
2. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic agents and thrombotic microangiopathy.
Garcia G; Atallah JP
J Oncol Pharm Pract; 2017 Mar; 23(2):135-142. PubMed ID: 26854265
[TBL] [Abstract][Full Text] [Related]
6. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M
Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018.
Saleem R; Reese JA; George JN
Am J Hematol; 2018 Sep; 93(9):E241-E243. PubMed ID: 29985540
[No Abstract] [Full Text] [Related]
8. Proteasome inhibitors: structure and function.
Nunes AT; Annunziata CM
Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
[TBL] [Abstract][Full Text] [Related]
9. Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.
Cassol CA; Williams MPA; Caza TN; Rodriguez S
Medicine (Baltimore); 2019 Sep; 98(39):e17148. PubMed ID: 31574818
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib-induced thrombotic microangiopathy. A case report.
Scheggi V; Merilli I; Cesaroni E; Alterini B
J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
[TBL] [Abstract][Full Text] [Related]
11. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
12. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.
Kozlowski P; Kameran Behnam K; Uggla B; Åström M
Eur J Haematol; 2020 Jun; 104(6):588-593. PubMed ID: 32115785
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
15. Real-world renal function among patients with multiple myeloma in the United States.
Mikhael J; Singh E; Rice MS
Blood Cancer J; 2021 May; 11(5):99. PubMed ID: 34021119
[No Abstract] [Full Text] [Related]
16. Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.
Skarbnik AP; Ma E; Lafeuille MH; Fortier J; Feldman T; Duh MS; van de Velde H; Niculescu L; Bonthapally V; Goy A
Leuk Lymphoma; 2017 Aug; 58(8):1968-1972. PubMed ID: 28092998
[No Abstract] [Full Text] [Related]
17. A review of thrombotic microangiopathies in multiple myeloma.
Portuguese AJ; Gleber C; Passero FC; Lipe B
Leuk Res; 2019 Oct; 85():106195. PubMed ID: 31404728
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J
Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313
[TBL] [Abstract][Full Text] [Related]
19. Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.
Hamad CD; Hoelscher ZC; Tchakarov A; Kala J
CEN Case Rep; 2022 Aug; 11(3):321-327. PubMed ID: 34997535
[TBL] [Abstract][Full Text] [Related]
20. [I. Proteasome inhibitor for treatment of multiple myeloma].
Murakami H; Saito T; Handa H
Gan To Kagaku Ryoho; 2013 May; 40(5):583-8. PubMed ID: 23957065
[No Abstract] [Full Text] [Related]
[Next] [New Search]
